Ibrahim Sherif, Spackman Erica, Suarez David L, Goraichuk Iryna V, Lee Chang-Won
Exotic and Emerging Avian Viral Diseases Unit, Southeast Poultry Research Laboratory, US National Poultry Research Center, Agricultural Research Service, US Department of Agriculture, 934 College Station Road, Athens, Georgia 30605, USA.
J Virol Methods. 2025 May;334:115127. doi: 10.1016/j.jviromet.2025.115127. Epub 2025 Feb 15.
Unprecedented H5N1 highly pathogenic avian influenza (HPAI) outbreaks are occurring around the world and there is growing interest in the use of vaccines in affected regions. Vaccination when properly applied can contribute to HPAI control by significantly reducing virus shedding and breaking the transmission chain, but it requires robust surveillance to ensure that international trade is not affected. Thus, it is imperative to establish a test to differentiate vaccinated only animals from vaccinated and then infected animals (DIVA). In this study, we applied enzyme-linked lectin assay (ELLA) to specifically detect N1 neuraminidase (NA) antibody by inhibition of NA activity and provide a proof-of-concept bench validation using reference and experimental serum samples. We used a wild-type low pathogenic H7N1 virus of North American lineage as the ELLA antigen. The NA inhibition ELLA (NI-ELLA) was evaluated for its specificity and sensitivity using reference and experimental samples. The results demonstrated that the NI-ELLA was highly specific with low background NI activity against influenza-negative sera from different species although varying level of cross-reactivity was observed against sera of different NA subtypes with highest cross-reactivity against N4 subtype sera. Using a conservative positive cut-off threshold of 50 % NI activity, NI-ELLA provides 100 % specificity with all reference sera of 9 different NA subtypes. The relative sensitivity of NI-ELLA was evaluated in detecting H5N1 infection in vaccinated and then challenged birds and NI-ELLA showed higher detection rate of H5N1 infection compared with commercial NP ELISAs and real-time RT-PCR. Overall, the NI-ELLA shows high specificity and sensitivity and has the potential for application in DIVA surveillance with further validation.
前所未有的H5N1高致病性禽流感(HPAI)疫情正在全球范围内爆发,受影响地区对疫苗使用的兴趣与日俱增。正确接种疫苗可通过显著减少病毒排放和切断传播链,有助于控制HPAI,但这需要强有力的监测,以确保国际贸易不受影响。因此,必须建立一种检测方法,以区分仅接种疫苗的动物和先接种疫苗后感染的动物(DIVA)。在本研究中,我们应用酶联凝集素测定法(ELLA),通过抑制NA活性特异性检测N1神经氨酸酶(NA)抗体,并使用参考血清和实验血清样本进行了概念验证的实验台验证。我们使用北美谱系的野生型低致病性H7N1病毒作为ELLA抗原。使用参考样本和实验样本评估了NA抑制ELLA(NI-ELLA)的特异性和敏感性。结果表明,NI-ELLA具有高度特异性,对来自不同物种的流感阴性血清的背景NI活性较低,尽管观察到对不同NA亚型血清的交叉反应水平不同,对N4亚型血清的交叉反应性最高。使用50% NI活性的保守阳性临界阈值,NI-ELLA对9种不同NA亚型的所有参考血清具有100%的特异性。评估了NI-ELLA在检测先接种疫苗后再受攻击的禽类中H5N1感染的相对敏感性,与商业NP ELISA和实时RT-PCR相比,NI-ELLA显示出更高的H5N1感染检测率。总体而言,NI-ELLA显示出高特异性和敏感性,有潜力在进一步验证后应用于DIVA监测。